AbbVie has received a number of interesting FDA approvals over the past months and are on track to be either approved or under review across all of Humira's primary indications. The company's Neuroscience division has seen excellent momentum off late. In addition, they experienced solid growth in their platforms, including aesthetics and hematological oncology portfolio. Based on our credit analysis, the company merits a Credit Evaluation Score of A with a stable outlook and as per our Financial ....
29 Jan 2022
AbbVie Inc: Detailed Credit Analysis & Financial Strength Evaluation Report (01/2022)
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
AbbVie Inc: Detailed Credit Analysis & Financial Strength Evaluation Report (01/2022)
- Published:
29 Jan 2022 -
Author:
Ishan Majumdar -
Pages:
15
AbbVie has received a number of interesting FDA approvals over the past months and are on track to be either approved or under review across all of Humira's primary indications. The company's Neuroscience division has seen excellent momentum off late. In addition, they experienced solid growth in their platforms, including aesthetics and hematological oncology portfolio. Based on our credit analysis, the company merits a Credit Evaluation Score of A with a stable outlook and as per our Financial ....